Effect of doxercalciferol (1a-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy
| Autor: | M.S. Parisi, B Oliveri, C Mautalen, J Somoza |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male musculoskeletal diseases Parathyroidectomy medicine.medical_specialty Calcitriol medicine.medical_treatment Parathyroid hormone Bone remodeling Bone Density Renal Dialysis Internal medicine medicine Humans Doxercalciferol Bone mineral Hyperparathyroidism business.industry General Medicine medicine.disease Endocrinology Parathyroid Hormone Nephrology Ergocalciferols Hyperparathyroidism Secondary Secondary hyperparathyroidism Bone Remodeling business medicine.drug |
| Zdroj: | Clinical Nephrology. 59:471-474 |
| ISSN: | 0301-0430 |
| DOI: | 10.5414/cnp59471 |
| Popis: | The efficacy and safety of the vitamin D analog, doxercalciferol (1alpha-hydroxyvitamin D2, 1alphaD2) in the treatment of secondary hyperparathyroidism in hemodialysis patients has been previously reported. We report these effect of 16-week 1alphaD2 treatment on mineral metabolism and bone mineral density (BMD) in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy, resistant to previous calcitriol treatment. Levels of iPTH, bone-specific alkaline phosphatase and serum type I collagen C telopeptide were above normal at baseline and were substantially decreased with 1alphaD2 treatment (-92%, -63% and -53%, respectively). BMD increased in all areas: total skeleton (+6.5%), lumbar spine (+6.9%) and total femur (+4.3%). The patient showed no hypercalcemia, and phosphorus levels remained between 3.3 and 6.2 mg/dl. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|